High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination

Molecular Medicine

Volumn 18, Issue 12, 2012, Pages 1499-1508

  Pohla, Heike ^a,b   Buchner, Alexander ^a,c   Stadlbauer, Birgit ^a   Frankenberger, Bernhard ^b   Stevanovic, Stefan ^d   Walter, Steffen ^e   Frank, Ronald ^f   Schwachula, Tim ^g   Olek, Sven ^g   Kopp, Joachim ^h   Willimsky, Gerald ^h   Stief, Christian G ^a,c   Hofstetter, Alfons ^a,c   Pezzutto, Antonio ^h   Blankenstein, Thomas ^h   Oberneder, Ralph ^c,i   Schendel, Dolores J ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e IMMATICS BIOTECHNOLOGIES GMBH   (Germany)

^f HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^g EPIONTIS GMBH   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ Urology Clinic Munich Planegg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CARBONATE DEHYDRATASE IX; CD4 ANTIGEN; EPITOPE; FLUOROURACIL; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 5; INTERLEUKIN 7 RECEPTOR; MATRILYSIN; NY ESO 1 ANTIGEN; PRUNE2 ANTIGEN; REGULATOR OF G PROTEIN SIGNALLING 5; SOMATOMEDIN BINDING PROTEIN 3; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION INTERMEDIARY FACTOR 1; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG RESPONSE; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; IMMUNOREACTIVITY; IMMUNOSTIMULATION; IN VIVO STUDY; KIDNEY CARCINOMA; KIDNEY METASTASIS; LYMPHOCYTE SUBPOPULATION; MYELOID DERIVED SUPPRESSOR CELL; NATURAL REGULATORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; SURVIVAL TIME; TH1 TH2 BALANCE; TUMOR IMMUNITY;

CANCER VACCINES; CARCINOMA, RENAL CELL; CYTOKINES; HUMANS; IMMUNITY; KIDNEY NEOPLASMS; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MYELOID CELLS; NEOPLASM METASTASIS; NEOPLASM STAGING; PEPTIDES; SURVIVAL ANALYSIS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS; TIME FACTORS; TREATMENT OUTCOME; VACCINATION;

EID: 84873489182     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2012.00221     Document Type: Article

References (42)

1. Frey K, et al. (2010) The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. J. Urol. 184:2540-8.
2. Escudier B, et al. (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 28:2144-50.
3. Wang Y, Wang XY, Subjeck JR, Shrikant PA, Kim HL. (2011) Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br. J. Cancer. 104:643-52.
4. Motzer RJ. (2003) Renal cell carcinoma: a priority malignancy for development and study of novel therapies. J. Clin. Oncol. 21:1193-4.
5. Simons JW, et al. (1997) Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colonystimulating factor gene transfer. Cancer Res. 57:1537-46.
6. Zhou X, et al. (2005) Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocytemacrophage colony-stimulating factor gene-transduced renal tumor cell vaccine. Cancer Res. 65:1079-88.
7. Antonia SJ, et al. (2002) Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J. Urol. 167:1995-2000.
8. Zhou J, et al. (2009) Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses. Cancer Immunol. Immunother. 58:1587-97.
9. Avigan DE, et al. (2007) Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J. Immunother. 30:749-61.
10. Buchner A, et al. (2010) Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma. Hum. Gene Ther. 21:285-97.
11. Frankenberger B, et al. (2005) Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs. Clin. Cancer Res. 11:1733-42.
12. Olek A, Oswald J, Walter J. (1996) A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res. 24:5064-6.
13. Wieczorek G, et al. (2009) Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res. 69:599-608.
14. Palmer PA, et al. (1992) Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann. Oncol. 3:475-80.
15. Zea AH, et al. (2005) Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65:3044-8.
16. Escudier B, et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356:125-34.
17. Motzer RJ, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356:115-24.
18. Curiel TJ, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10:942-9.
19. Liotta F, et al. (2011) Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int. 107:1500-6.
20. Finke JH, et al. (2008) Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res. 14:6674-82.
21. Adotevi O, et al. (2010) A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J. Immunother. 33:991-8.
22. Dannull J, et al. (2005) Enhancement of vaccinemediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115:3623-33.
23. Westermann J, et al. (2011) Allogeneic genemodified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study. Gene Ther. 18:354-63.
24. Ahmadzadeh M, Rosenberg SA. (2006) IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood. 107:2409-14.
25. van der Vliet HJ, et al. (2007) Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin. Cancer Res. 13:2100-8.
26. Berntsen A, Brimnes MK, thor Straten P, Svane IM. (2010) Increase of circulating CD4+CD25high Foxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2. J. Immunother. 33:425-34.
27. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. (2003) L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 24:302-6.
28. Kasic T, et al. (2011) Modulation of human T-cell functions by reactive nitrogen species. Eur. J. Immunol. 41:1843-9.
29. Kusmartsev S, Gabrilovich DI. (2003) Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J. Leukoc. Biol. 74:186-96.
30. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. (2010) Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 70:68-77.
31. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. (2009) Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J. Immunol. 183:937-44.
32. Huang B, et al. (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66:1123-31.
33. Diaz-Montero CM, et al. (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58:49-59.
34. Ko JS, et al. (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15:2148-57.
35. Kusmartsev S, et al. (2008) Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 14:8270-8.
36. Callard R, George AJ, Stark J. (1999) Cytokines, chaos, and complexity. Immunity. 11:507-13.
37. Kyte JA, et al. (2009) Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. Cancer Immunol. Immunother. 58:1609-26.
38. Guida M, Casamassima A, Monticelli G, Quaranta M, Colucci G. (2007) Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors. J. Transl. Med. 5:51.
39. Mocellin S, Marincola FM, Young HA. (2005) Interleukin-10 and the immune response against cancer: a counterpoint. J. Leukoc. Biol. 78:1043-51.
40. De Vleeschouwer S, Spencer Lopes I, Ceuppens JL, Van Gool SW. (2007) Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells. J. Neurooncol. 84:131-40.
41. Schwaab T, et al. (2009) Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (interleukin 2) and IFN-(2a therapy in metastatic renal cell carcinoma patients. Clin. Cancer Res. 15:4986-92.
42. Panelli MC, et al. (2004) Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J. Transl. Med. 2:17.